Biontech starts phase 1 clinical trial for prophylactic herpes simplex virus-2 vaccine candidate bnt163

Mainz, germany, december 21, 2022 – biontech se (nasdaq: bntx, “biontech” or the "company”) today announced that the first subject was dosed in a first-in-human phase 1 clinical research study with bnt163, a herpes simplex virus (hsv) vaccine candidate for the prevention of genital lesions caused by hsv-2 and potentially hsv-1. the trial ( nct05432583 ) will evaluate the safety, tolerability, and immunogenicity of bnt163. the mrna vaccine encodes three hsv-2 glycoproteins with the aim of helping to prevent hsv cellular entry and spread, as well as counteract the immunosuppressive properties of hsvs.
BNTX Ratings Summary
BNTX Quant Ranking